
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
It's 10:45 p.m. on a Sunday. You're winding down from an enjoyable weekend when, suddenly, the sound of your pager summons you. There's a call from your local hospital.